When we eat food, our stomach releases a hormone that helps the body regulate hunger and blood sugar levels. This hormone is called GLP-1 (glucagon-like peptide-1). The actions of GLP-1 are the target of Wegovy.
Wegovy and this class of medications are known as GLP-1 receptor agonists (GLP-1s). They mimic the actions of the hormone GLP-1.
Wegovy helps your pancreas release more insulin to lower blood sugar levels, delay emptying food from the stomach (also called gastric emptying), and lowers hunger by communicating directly with the brain’s appetite control centre, the hypothalamus, to lower food-seeking behaviours.
2) How much weight will I lose on Wegovy?
Wegovy leads to an average weight loss of 15-20% after 68 weeks and is more effective than other weight-loss injections, like Saxenda.
A meta-analysis investigated the impact of semaglutide (Wegovy) and liraglutide (Saxenda) and suggested that semaglutide was more effective at lowering blood sugar levels (as measured by HbA1c).
The study showed that a 0.5mg dose of semaglutide led to a more significant reduction (0.17%) in HbA1c than liraglutide.
The 1mg dose of semaglutide showed a further benefit compared to 1.2mg and 1.7mg of Saxenda at 0.47% and 0.3%, respectively.
However, the studies used to compare the two drugs were from individual trials, comparing one of the medications with a placebo (a sugar pill). They hadn’t yet been compared directly with one another.
Fortunately, a randomised controlled trial was conducted in 2022 investigating the impact of semaglutide and liraglutide on weight loss in individuals living with obesity.
The results showed that the participants in the semaglutide group lost 15.8% of their body weight compared to 6.4% in the liraglutide group.
Semaglutide was also shown to be more tolerated than liraglutide. 13.5% of participants in the semaglutide group discontinued their treatment due to side effects, compared to 27.6% with liraglutide.
Over 80% of participants in both groups reported common side effects and GI-related issues such as constipation, cramping, bloating, and diarrhoea.
Due to the positive results from these studies, Semaglutide was made available in 2023 in the UK after the U.S. approved the drug in 2021.
How does Wegovy compare to weight loss without medication?
Lifestyle interventions without semaglutide tend to lead to an average weight loss of around 5-10%.
Losing and maintaining weight loss of more than 10% is associated with significantly reducing complications related to obesity, including hypertension, type 2 diabetes, and heart disease.
A recent paper published in The Lancet showed that nearly 20% of participants in lifestyle interventions without medications gain weight, around 40% lose between 1-10% of their body weight, and just 13% lose more than 10%.
In comparison, less than 5% of participants combining semaglutide with lifestyle interventions gain weight, around 10% lose between 1-10%, and 87% lose more than 10%.
So, 47% more people lose more than 10% of body weight on lifestyle interventions with semaglutide compared to lifestyle interventions alone.
Key points:
- A meta-analysis compared the impact of semaglutide and liraglutide on lowering blood sugar levels (measured by HbA1c) and suggested that semaglutide was more effective than liraglutide
- A randomised controlled trial conducted in 2022 investigated the impact of semaglutide and liraglutide on weight loss in individuals living with obesity
- The results showed that semaglutide was more effective at weight loss (15.8% body weight loss) than liraglutide (6.4% body weight loss)
- Semaglutide was also better tolerated than liraglutide, with fewer participants discontinuing treatment due to side effects, but GI-related issues were common in both groups
- Lifestyle interventions without semaglutide average around 5-10% weight loss, and less people achieve clinically significant weight loss without semaglutide
3) What’s the difference between Wegovy and Ozempic?
The only difference between Wegovy and Ozempic® is the available dose, with Wegovy available up to 2.4 mg, compared to 1 mg with Ozempic®.
Initial research on semaglutide focused on Ozempic® and doses between 0.5 mg and 1 mg. However, the studies found that 20-30% of individuals on the medication didn’t reach the treatment targets for reducing their blood sugar levels.
A randomised controlled trial with 961 participants compared the impact of a once-weekly dose of 1mg or 2mg of semaglutide on blood glucose levels and weight loss for people living with type 2 diabetes.
You might expect that a doubling of the dose would lead to a doubling of the effect.
However, the human body is a bit more complex than that. Medications (and hormones in the body) often have a ‘ceiling effect’ where the relationship between the exposure and the effect is no longer linear.
The results showed that 1 mg of semaglutide reduced HbA1c (average blood glucose) by 1.9% compared to 2.2% in the 2 mg group.
A similar trend was shown with weight loss. 1 mg of semaglutide led to an average weight loss of 6 kg compared to 6.9 kg in the 2 mg group. Interestingly, both groups reported similar levels of adverse events and side effects.
So, the higher dose of semaglutide that you’ll receive with Wegovy will likely lead to more significant reductions in weight loss and blood sugar levels without experiencing more adverse events or side effects.
However, you must monitor your medication responses and determine your tolerance level. You might tolerate a higher dose, but you might not.
The research on these medications has shown that the most severe side effects are reported when the dose of the medication is increased while your body adjusts.
You might determine that any side effects are worthwhile to help you improve your health conditions and lose weight. But you must contact your healthcare team and discuss any side effects to ensure this is monitored and the dose adjusted to suit your needs.
Key points:
- Most research with semaglutide is with the doses of 0.5 mg, and 1mg that you have with Ozempic®
- Only one trial has compared the impact of 1 mg to 2 mg of semaglutide and found it did lead to more significant reductions in weight and blood sugar levels
- However, the differences weren’t as significant as you might expect and the dose that’s best for you will depend on your tolerance level and weight loss goals
- You must report any side-effects with your healthcare team and adjust your dose accordingly
Take home message
Weight-loss injections are designed as additional tools for weight management interventions and shouldn’t be considered lifelong medications.
Instead, they should be used to help you kickstart your weight loss and healthy journey while you commit to living a healthier lifestyle.
Consider the use of antidepressants for people living with depression. They’re not designed to cure the condition. Instead, they’re designed to allow room for therapy to treat the condition’s underlying cause.
Ozempic and other weight loss injections, like Mounjaro, are similar. They can allow you to make lifestyle changes to support long-term weight loss maintenance.
Ozempic can help silence food-related thoughts and also give you a boost of confidence with more immediate weight-loss results.
This helps to buy you the time and headspace to understand why your body may have struggled to lose weight previously, and to build new long-term healthy habits.
The core focus of our medication programmes is to calm down the feeling of food noise, lower your cravings, and allow you to build healthier habits to keep the weight off for good.
The ultimate goal is to make losing weight feel second nature.
Second Nature’s medication-supported programmes
Second Nature has two medication-supported programmes: a Wegovy weight-loss programme and a Mounjaro weight-loss programme. Ozempic is no longer available in the UK for weight loss.
If you’ve made the decision to try Wegovy or Mounjaro (assuming you’re eligible), why should you choose Second Nature over other medication providers?
For peace of mind.
Second Nature has worked with the NHS for over 6 years providing weight-loss programmes across the UK.
Whilst our Wegovy and Mounjaro weight-loss programmes are private and not currently used by the NHS, we’ve built the programmes with a focus on scientific evidence, patient safety, and data security.
We hope that our 6+ years of working with the NHS and building a track record of effective weight-loss results will give you peace of mind to give us a try.
